| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Avanos Medical, Inc.$24.99
0 (0%)
F 17Pipeline Score MedTech · Commercial
Market Cap
1.17 B
EPS
-1.61
P/E Ratio
-15.55 $
Value Trade
58.72 M
SEC Financials
Q1 2026Dilution Risk
35%Revenue
182.20 M
R&D Expenses
5.20 M
Operating CF
-12.30 M
Total Assets
1.05 B
Total Liabilities
268.00 M
Equity
782.10 M
D/E Ratio
12,345
-0.4 %
Week
-0.2 %
1 Month
61.8 %
3 Month
124.54 %
6 Month
-38.49 %
5 Year
-34.41 %
All Time
Cash Data
Cash Position
65.60 M
Monthly Burn
4.10 M
Runway
13.2 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
2.08 M
52 Week Range
9.30 - 25.49
% held by Insiders
2.77 %
% held by Institutions
90.98 %
Enterprise Value
1.24 B
Total Shares
46.82 M
Short %
3.95 %
Float Shares
44.34 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Avanos Medical, Inc.
2Total events
0Upcoming
2Tier-1 (high impact)
2026 – 2026Coverage
Event history 2
TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
TBD
▲AcquisitionCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 17%
Micro Cap (rank 759 of 913)
Percentile RankAvanos Medical, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AVNS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AVNS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AVNSAmerican Industrial Partners Completes Acquisition of Avanos Medical, Inc.
American Industrial Partners has successfully acquired Avanos Medical, Inc. for about $1.272 billion. As a result of this merger, Avanos stockholders will receive $25.00 per share, and the company will transition to a private entity. Both AIP and Avanos executives express optimism about future growth and innovation following the acquisition.
Read more →AVNSAvanos Medical, Inc. Stockholders Approve Acquisition by American Industrial Partners
Avanos Medical, Inc. announced that its stockholders have overwhelmingly approved the acquisition by American Industrial Partners, with 99.75% of shares voting in favor. The acquisition will allow stockholders to receive $25.00 per share in cash. The transaction is expected to close by July 27, 2026, following customary closing conditions.
Read more →AVNSAvanos Medical, Inc. and American Industrial Partners Receive Required Regulatory Approvals for Pending Merger
Avanos Medical, Inc. and American Industrial Partners have secured all necessary regulatory approvals for their pending merger. The transaction is expected to close by July 27, 2026, pending stockholder approval and other customary conditions. Avanos CEO David C. Pacitti expressed optimism about the merger's potential to drive innovation and growth.
Read more →AVNSAvanos Medical, Inc. Announces First Quarter 2026 Results
Avanos Medical, Inc. reported its first quarter 2026 results, highlighting an 8.8% increase in total net sales to $182.2 million, driven by strong performance in the Specialty Nutrition Systems segment. The company generated diluted earnings per share of $0.11, down from $0.14 a year ago. Additionally, Avanos announced a definitive agreement to be acquired by American Industrial Partners for $1.272 billion.
Read more →AVNS▲ +69.5%on this news
Avanos Medical, Inc. Agrees To Be Acquired by American Industrial Partners for Approximately $1.272 Billion
Avanos Medical, Inc. has agreed to be acquired by American Industrial Partners for approximately $1.272 billion. Stockholders will receive $25.00 per share, reflecting a premium over recent stock prices. The acquisition is expected to close in the second half of 2026, pending regulatory approvals. Avanos will become a private company post-transaction.
Read more →AVNS▲ +69.5%on this news
Document Investor Contact Scott Galovan Avanos Medical, Inc. Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. CorporateCommunications Avanos.com Avanos Medical, Inc. Announces First Quarter
Avanos Medical, Inc. reported its first quarter 2026 financial results, showcasing an 8.8% increase in total net sales, predominantly driven by the Specialty Nutrition Systems segment. Despite the positive growth, net income and adjusted earnings per share experienced a decline compared to the prior year. The company is also in the process of being acquired by American Industrial Partners in an all-cash transaction valued at $1.272 billion. However, the Pain Management and Recovery segment reported operating losses, indicating operational challenges.
Read more →AVNS▲ +69.5%on this news
year ended
Avanos Medical, Inc. has announced a definitive agreement to be acquired by American Industrial Partners for approximately $1.272 billion. Stockholders will receive $25.00 per share in cash, reflecting a significant premium over previous stock prices. This acquisition is seen as a strategic move to enhance Avanos' growth and innovation in the medical technology sector. The transaction is expected to close in the second half of 2026, pending necessary approvals and conditions.
Read more →AVNSAvanos Medical, Inc. to Present at the 2026 Citizens Life Sciences Conference
Avanos Medical, Inc. will present at the 2026 Citizens Life Sciences Conference on March 11. CEO Dave Pacitti and CFO Scott Galovan will participate in a fireside chat at 1:05 p.m. ET. The presentation will be available via webcast on the company's website, ensuring accessibility for investors.
Read more →AVNSAvanos Medical, Inc. to Nominate James Cunniff and William Burke to Board of Directors
Avanos Medical, Inc. announced the nomination of James Cunniff and William Burke as independent directors for its Board at the upcoming 2026 Annual Meeting. Cunniff, with extensive experience in medical technology, and Burke, a finance expert, are expected to contribute significantly to the company's strategic priorities. The nominations follow a cooperation agreement with Bradley L. Radoff.
Read more →AVNSSEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION. Detailed information regarding the identity of potential participants, and their direct or indirect interests, b
Avanos Medical, Inc. has announced plans to nominate James Cunniff and William Burke as independent directors during its 2026 Annual Meeting. This decision comes after a cooperation agreement with investor Bradley L. Radoff and his affiliates. The nominees bring extensive experience from their respective roles in medical technology and finance, with the aim to enhance the board's capabilities. The company emphasizes the strategic importance of these nominations for its long-term success and improvement in its governance structure.
Read more →AVNS▼ -10.4%on this newsshared move
EARNINGS RELEASE Document Investor Contact Scott Galovan Avanos Medical, Inc. 470-562-2692 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. CorporateCommunications Avanos.com Avanos Medical,
Avanos Medical, Inc. reported its fourth quarter and full-year 2025 results, highlighting exceeded revenue expectations and organic growth of 6% in strategic segments. The company's operating income for the year showed significant improvement, reflecting a reduced net loss compared to the previous year. Despite these positive results, adjusted EBITDA declined, and the company experienced a substantial non-cash goodwill impairment. Looking forward, Avanos projects net sales for 2026 to be between $700 million and $720 million.
Read more →AVNS▼ -5.7%on this news
Document Investor Contact Scott Galovan Avanos Medical, Inc. 470-562-2692 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. CorporateCommunications Avanos.com Avanos Medical, Inc. Announces T
Avanos Medical, Inc. reported its third quarter 2025 financial results, showing a 4.3% increase in total net sales to $177.8 million. The company achieved double-digit growth in its Specialty Nutrition Systems segment and completed the acquisition of Nexus Medical, which adds complementary technology. However, Avanos also experienced a net loss of $1.4 million and recorded a significant impairment charge. Despite these challenges, the company has raised its revenue and adjusted EPS guidance for the full year.
Read more →AVNSDocument Avanos Medical Acquires Nexus Medical to Strengthen Nutrition and Medication Delivery in Critical Care ALPHARETTA, Ga.
Avanos Medical announced the acquisition of Nexus Medical, a maker of the TKO anti-reflux needleless connector technology. This acquisition aims to bolster Avanos' Specialty Nutrition Systems business, particularly in neonatal and pediatric intensive care. The TKO technology is designed to improve safety and reliability in medication and nutrition delivery. Both executives from Avanos expressed confidence in the acquisition's positive impact on patient care and financial performance.
Read more →AVNS▼ -12.1%on this news
Document Investor Contact Scott Galovan Avanos Medical, Inc. 470-562-2692 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. CorporateCommunications Avanos.com Avanos Medical, Inc. Announces S
Avanos Medical, Inc. reported a challenging second quarter for 2025 with a significant net loss of $76.8 million, largely due to a goodwill impairment charge. Despite a slight increase in net sales driven by the Specialty Nutrition Systems segment, the company's overall performance was dampened by decreased sales in surgical pain recovery. Adjusted EBITDA fell to $17.0 million, down from $26.8 million a year ago, highlighting ongoing financial struggles amidst operational adjustments. Avanos maintains its revenue guidance for 2025 despite these hurdles.
Read more →AVNS▲ +5.4%on this news
Document Investor Contact Scott Galovan Avanos Medical, Inc. 470-562-2692 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. CorporateCommunications Avanos.com Avanos Medical, Inc. Announces F
Avanos Medical, Inc. has reported its financial results for the first quarter of 2025, highlighting a slight increase in net sales and significant improvement in net income. The company's new CEO, David Pacitti, emphasized the positive transformation efforts that position the company for future growth. However, the gross margin has declined compared to the previous year, and the company has adjusted its earnings guidance downward due to anticipated tariffs. Overall, while there are positive signs of growth, challenges remain.
Read more →AVNSDocument Media Contact Katrine Kubis Avanos Medical, Inc. CorporateCommunications Avanos.com Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer ALPHARETTA, Ga.
Avanos Medical, Inc. has appointed David Pacitti as its new Chief Executive Officer, effective April 14, 2025. Pacitti brings extensive experience from his previous role at Siemens Medical Solutions, where he led various strategic initiatives and operational functions. His leadership is anticipated to drive growth and success for Avanos, as expressed by the company's board chair. Pacitti aims to enhance the company's portfolio of medical device solutions focused on improving patient quality of life.
Read more →AVNSDocument Investor Contact Michael Greiner Avanos Medical, Inc. 470-562-2692 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. CorporateCommunications Avanos.com Avanos Medical, Inc. Announces
Avanos Medical, Inc. announced its fourth quarter and full-year 2024 financial results, showcasing a 5% organic growth in Q4. Despite achieving $83 million in free cash flow, the company reported a substantial operating loss of $418.5 million, along with a net loss from continuing operations of $397 million. The results reflect ongoing challenges, including a goodwill impairment charge of $436.7 million, but the interim CEO expressed confidence in long-term strategies for margin improvement.
Read more →AVNSFor further information Investor Contact Michael Greiner, Avanos Medical, Inc., Investor.Relations Avanos.com Media Contact Katrine Kubis, Avanos Medical, Inc., CorporateCommunications Avanos.com
Avanos Medical, Inc. announced the appointment of Indrani Franchini as an independent member of its board of directors. Franchini brings extensive experience from significant roles at Alnylam Pharmaceuticals and Alexion Pharmaceuticals, which is expected to be beneficial for Avanos. With this appointment, the board now has six directors, maintaining a strong focus on diversity and independent governance. Avanos continues its commitment to addressing critical healthcare needs through its innovative medical solutions.
Read more →AVNS▼ -17.2%on this news
Document Investor Contact Michael Greiner Avanos Medical, Inc. 470-562-2692 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. CorporateCommunications Avanos.com Avanos Medical, Inc. Reports P
Avanos Medical, Inc. reported preliminary financial results for Q4 and FY 2023, revealing a decrease in net sales and a revised outlook for 2024 revenue. The company expects Q4 net sales to fall between $170 million and $173 million, a significant decline from last year. Key factors contributing to this decline include underperformance in hyaluronic acid products and changes in distributor ordering patterns. Despite these challenges, the CEO remains optimistic about the company's strategic transformation initiatives aimed at 2025.
Read more →AVNSavnsform8k_6202023xex991 Investor Day
Avanos Healthcare held its Investor Day on June 20, 2023, where CEO Joe Woody outlined the company's strategic direction through 2025. The discussion highlighted the ongoing transformation initiatives and significant investments in M&A that are expected to drive revenue growth. Avanos aims to optimize its product portfolio and enhance its operating profitability while facing risks such as competition and pandemic-related challenges. The company is focused on solidifying its presence in the Digestive Health and Pain Management markets.
Read more →AVNSnot relate solely to historical or current facts, and can generally be identified by the use of words such as "will," "expect," and similar expressions. The forward-looking statements include statements regarding the imp
Avanos Medical, Inc. has announced the sale of its Respiratory Health business to SunMed Group Holdings, accelerating the company's focus on higher-margin markets. This strategic move is part of Avanos' ongoing transformation process aimed at optimizing its portfolio. The transaction is set to close in late 2023 and is expected to strengthen Avanos' financial position. The company plans to provide transition services post-sale as SunMed integrates the Respiratory Health assets into its offerings.
Read more →AVNSWith this new appointment, the Avanos board now comprises six directors, five of whom are independent, including two women, one of whom is ethnically diverse. About Avanos Medical, Inc. Avanos Medical, Inc. (NYSE AVNS) i
Avanos Medical, Inc. has appointed Dr. Lisa Egbuonu-Davis to its board of directors, expanding its independent membership to five out of six directors. Dr. Egbuonu-Davis brings a strong background in healthcare, having previously held leadership positions at companies like Sanofi and Pfizer. Her addition is seen as valuable for Avanos as it aims to innovate healthcare solutions, particularly in reducing opioid reliance and improving patient outcomes. This move reflects Avanos' commitment to enhancing board diversity and operational expertise.
Read more →AVNSInvestor Contact Michael Greiner Avanos Medical, Inc. Investor.Relations avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. CorporateCommunications avanos.com Avanos Medical, Inc. Appoints Sudhakar Varshney as S
Investor Contact Michael Greiner Avanos Medical, Inc. Investor.Relations avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. CorporateCommunications avanos.com Avanos Medical, Inc. Appoints Sudhakar Varshney as Senior Vice President, Global Supply Chain Procu
Read more →AVNSin more than 90 countries. For more information, visit www.avanos.com and follow Avanos Medical on Twitter ( AvanosMedical), LinkedIn and Facebook. SOURCE Avanos Medical, Inc. Note Regarding Forward-Looking Statements Th
Investor Contact Michael Greiner Avanos Medical, Inc. 470-562-2692 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. 470-448-5561 CorporateCommunications Avanos.com AVANOS MEDICAL, INC. ANNOUNCES SHARE REPURCHASE AUTHORIZATION ALPHAR
Read more →AVNSstatements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as may, believe", will, "expect," "project," "estimate," "anticipate,"
Investor Contact Michael Greiner Avanos Medical, Inc. 470-562-2692 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. 470-448-5561 CorporateCommunications Avanos.com Avanos Medical, Inc. Announces Agreement to Acquire OrthogenRX, Inc.
Read more →AVNSDocument Investor Contact Michael Greiner Avanos Medical, Inc. 470-562-2692 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. 470-448-5561 CorporateCommunications Avanos.com Avanos Medical, I
Investor Contact Michael Greiner Avanos Medical, Inc. 470-562-2692 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. 470-448-5561 CorporateCommunications Avanos.com Avanos Medical, Inc. Announces Third Quarter 2021 Results ALPHARETTA
Read more →AVNSInvestor Contact Dave Crawford Avanos Medical, Inc. 470-448-5177 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. 470-448-5561 CorporateCommunications Avanos.com Avanos Medical, Inc. Appoint
Investor Contact Dave Crawford Avanos Medical, Inc. 470-448-5177 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. 470-448-5561 CorporateCommunications Avanos.com Avanos Medical, Inc. Appoints Moji James as Senior Vice President Gener
Read more →AVNSDocument Investor Contact Dave Crawford Avanos Medical, Inc. 470-448-5177 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. 470-448-5561 CorporateCommunications Avanos.com Avanos Medical, Inc
Investor Contact Dave Crawford Avanos Medical, Inc. 470-448-5177 Investor.Relations Avanos.com Media Contact Katrine Kubis Avanos Medical, Inc. 470-448-5561 CorporateCommunications Avanos.com Avanos Medical, Inc. Announces First Quarter 2021 Results ALPHARETTA,
Read more →AVNSAvanos Medical, Inc.
Investor Contact: Dave Crawford Avanos Medical, Inc. 470-448-5177 Investor.Relations@Avanos.com Media Contact: Elizabeth Volpe Brunswick Group 212-333-3810 Avanos@BrunswickGroup.com Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2019 Results, Provid
Read more →AVNSAvanos Medical Appoints Michael C.
Investor Contact: Dave Crawford Avanos Medical, Inc. 470-448-5177 Investor.Relations@Avanos.com Media Contact: Elizabeth Volpe Brunswick Group 212-333-3810 Avanos@BrunswickGroup.com Avanos Medical Appoints Michael C. Greiner as Chief Financial Officer ALPHARETTA
Read more →AVNSInvestor Contact: Dave Crawford Avanos Medical, Inc. 470-448-5177 Investor.Relations@Avanos.com Media Contact: Elizabeth Volpe, Marleen Geerlof Brunswick Group 212-333-3810 Avanos@BrunswickGroup.com Avanos Medical, Inc.
Investor Contact: Dave Crawford Avanos Medical, Inc. 470-448-5177 Investor.Relations@Avanos.com Media Contact: Elizabeth Volpe, Marleen Geerlof Brunswick Group 212-333-3810 Avanos@BrunswickGroup.com Avanos Medical, Inc. Announces Third Quarter 2018 Results, Affi
Read more →AVNSInvestor Contact: Dave Crawford Halyard Health, Inc. 470-448-5177 Investor.Relations@HYH.com Media Contact: Raul Damas / Marleen Geerlof Brunswick Group (212) 333-3810 Halyard@BrunswickGroup.com Halyard Health Announces
Investor Contact: Dave Crawford Halyard Health, Inc. 470-448-5177 Investor.Relations@HYH.com Media Contact: Raul Damas / Marleen Geerlof Brunswick Group (212) 333-3810 Halyard@BrunswickGroup.com Halyard Health Announces Corporate Rebranding, Changes Name to Avano
Read more →AVNSHalyard Health, Inc.
Investor Contact: Dave Crawford Halyard Health, Inc. 470-448-5177 Investor.Relations@HYH.com Media Contact: Casey Becker Brunswick Group 646-292-3292 Halyard@BrunswickGroup.com Halyard Health, Inc. Announces First Quarter 2018 Results ALPHARETTA, Ga., May 2, 201
Read more →AVNSlevels from third-party payors; a significant increase in product liability claims; the impact of investigative and legal proceedings and compliance risks; the impact of the federal legislation to reform the United State
Halyard Health Announces CEO Transition Abernathy to Retire as CEO; Continue as Chairman Woody Elected as CEO; Member of the Board of Directors ALPHARETTA, Ga., (June 23, 2017) - Halyard Health, Inc., today announced that Robert E. Abernathy will retire as CEO, effective June
Read more →AVNSHalyard Health Announces Agreement to Acquire CORPAK MedSystems Acquisition Enhances Halyard s Growing Medical Devices Segment by Expanding the Company s Digestive Health Product Portfolio ALPHARETTA, Ga.
Halyard Health Announces Agreement to Acquire CORPAK MedSystems Acquisition Enhances Halyard s Growing Medical Devices Segment by Expanding the Company s Digestive Health Product Portfolio ALPHARETTA, Ga., April 11, 2016 /PRNewswire/ Halyard Health, Inc. (NYSE: HYH) announced t
Read more →AVNShyh2q2015form8kex99.1 Investor Contact: Dave Crawford Halyard Health, Inc. 470-448-5177 Investor.Relations@HYH.com Media Contact: Kristen Perry MSLGROUP 781-684-0770 Corp_hyh@mslgroup.com Halyard Health, Inc. Announces S
Investor Contact: Dave Crawford Halyard Health, Inc. 470-448-5177 Investor.Relations@HYH.com Media Contact: Kristen Perry MSLGROUP 781-684-0770 Corp_hyh@mslgroup.com Halyard Health, Inc. Announces Second Quarter 2015 Results ALPHARETTA, Aug. 4, 2015/PRNewswire/
Read more →AVNShyh1q2015form8kex99.1 Investor Contact: Dave Crawford Halyard Health, Inc. 470-448-5177 Investor.Relations@HYH.com Media Contact: Kristen Perry MSLGROUP 781-684-0770 Corp_hyh@mslgroup.com Halyard Health, Inc. Announces F
Investor Contact: Dave Crawford Halyard Health, Inc. 470-448-5177 Investor.Relations@HYH.com Media Contact: Kristen Perry MSLGROUP 781-684-0770 Corp_hyh@mslgroup.com Halyard Health, Inc. Announces First Quarter 2015 Results and Affirms 2015 Net Sales Growth and
Read more →AVNSHALYARD HEALTH, INC. SELECTED BUSINESS SEGMENT DATA (unaudited) Percentage Change - Net Sales vs. Prior Year Three Months Ended
Investor Contact: Dave Crawford Halyard Health, Inc. 470-448-5177 Dave.Crawford@HYH.com Media Contact: Kristen Perry MSLGROUP 781-684-0770 Corp_hyh@mslgroup.com Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook ALPHARETTA, Mar. 4, 2015/PRNews
Read more →AVNSJessica Van Derven HALYARD HEALTH +1.770.587.8709 jessica.vanderven@hyh.com Laura Weitzenhoff MSLGROUP 781-684-0770 Corp_hyh@mslgroup.com Halyard Health Debuts as Public Company Following Spinoff Shares of new medical te
jessica.vanderven@hyh.com Corp_hyh@mslgroup.com Debuts as Public Company Following Spinoff Shares of new medical technology company begin trading on the New York Stock Exchange ALPHARETTA, Ga. Nov. 3, 2014 Halyard Health (NYSE:HYH), a global medical technology company focused
Read more →AVNSLegal Disclaimer Legal Disclaimer PRELIMINARY FINANCIAL RESULTS This presentation contains Halyard Health s preliminary financial results for the quarter ended
Please see our Unaudited Pro Forma Condensed Combined Financial Statements included in our Registration Statement on Form 10 (as amended) filed with the Securities and Exchange Commission for a description of the adjustments to the items below for the year ended December 31, 2013
Read more →Competitive Position
How AVNS ranks across every disease it competes inCompetitive Position is a premium feature
See how AVNS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial